

**AMENDMENTS TO THE CLAIMS**

**This listing of claims will replace all prior versions and listings of claims in the application:**

**LISTING OF CLAIMS:**

Claims 1-36. (Canceled)

Claim 37. (Currently amended) An isolated peptide~~polypeptide~~ consisting of the amino acid sequence of ~~SEQ ID NO: 267 or a peptide fragment thereof, wherein said fragment is selected from the group consisting of: SEQ ID NO: 185, SEQ ID NO: 186, SEQ ID NO: 187, and SEQ ID NO: 188.~~

Claim 38. (Canceled)

Claim 39. (Currently amended) The isolated ~~polypeptide or peptide fragment of~~ claim 37, wherein said ~~polypeptide or peptide fragment~~ is recognized by a cytotoxic T lymphocyte in an HLA-A2 restricted manner, and/or induces a cytotoxic T lymphocyte in an HLA-A2-restricted manner.

40. (Currently Amended) A pharmaceutical composition comprising ~~the~~at least one ~~polypeptide or peptide fragment~~ of claim 37 and a pharmaceutically acceptable carrier.

Claims 41-42. (Canceled)

43. (Previously presented) A method for inducing a cytotoxic T lymphocyte, wherein the method comprises contacting peripheral blood mononuclear cells with ~~the at least one polypeptide or peptide fragment of claim 37 in vitro.~~

Claims 44-48. (Canceled)

49. (Currently amended) A method for screening for a compound that enhances recognition of the ~~polypeptide or peptide fragment of claim 37~~ by an HLA-A2 restricted cytotoxic T lymphocyte, wherein said method comprises:  
contacting said ~~polypeptide or peptide fragment~~ with a test compound, and  
~~determining whether said test compound enhances said recognition by measuring IFN- $\gamma$  production from said cytotoxic T lymphocyte in the presence and absence of said test compound,~~  
wherein said recognition is enhanced by said test compound if IFN- $\gamma$  production is higher in the presence of said test compound as compared to in the absence of said test compound.

50. (Currently amended) A method for screening for a compound that enhances recognition of ~~the said polypeptide or peptide fragment of claim 37~~ by an HLA-A2-restricted cytotoxic T lymphocyte, wherein said method comprises:

contacting HLA-A2+ cells that have been pulsed with said peptide fragment selected from the group consisting of SEQ ID NO: 185, SEQ ID NO: 186, SEQ ID NO: 187, and SEQ ID NO: 188, with said cytotoxic T lymphocyte, and in the presence and absence of a test compound, wherein said cytotoxic T lymphocyte recognizes a complex of the peptide with the HLA-A2 molecule;

~~and determining whether said compound enhances said recognition by measuring IFN- $\gamma$  production from said cytotoxic T lymphocyte in the presence and absence of said test compound, wherein said recognition is enhanced by said test compound if IFN- $\gamma$  production is higher in the presence of said test compound as compared to in the absence of said test compound.~~

Claims 51-55. (Canceled)

56. (Currently amended) A reagent kit comprising ~~at least one member selected from the group consisting of: a polypeptide or the peptide fragment of claim 37, an antibody that immunologically recognizes said polypeptide or peptide fragment, a polynucleotide encoding said polypeptide or peptide fragment or complementary strand thereof, a recombinant expression vector that expresses said polypeptide or peptide fragment, and a transformant harboring said expression vector, and~~  
a buffered solution.